Identifying and Solving Top Challenges to Oncology Biomarker TestingVideo Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library
Drs. David Rimm and Roy Herbst identify the top challenges in the area of biomarker testing as well as solutions to these challenges, including availability of sufficient tissue for a large number of biomarker assays, the time some biomarker tests require for completion, the need for a tight association of test results with clinical outcomes, and the development of companion diagnostics for certain immunotherapies.
Dr. Ajai Chari talks about risk-based treatment for myeloma as the beginning of personalized medicine in the field. The 2 most recent advances are the increased use of proteasome inhibitors for those with the 4;14 translocation and treating those identified with high molecular risk more aggressively.
Dr. Alex Adjei addresses the high cost of cancer medicines and suggests various ways to improve cost-effectiveness.